Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Charlotte, NC
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Statesville, NC
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Statesville, NC
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
mi
from
Springdale, OH
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
mi
from
Springdale, OH
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philidelphia, PA
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philidelphia, PA
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Warminster, PA
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Warminster, PA
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Fort Worth, TX
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Madison, WI
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated:  8/15/2016
University of Missouri, Department of Internal Medicine
mi
from
Columbia, MO
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated: 8/15/2016
University of Missouri, Department of Internal Medicine
mi
from
Columbia, MO
Click here to add this to my saved trials
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®), to Assess the Dose Proportionality of Epanova™, and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple Doses of Epanova™ and Vascepa® in Healthy Normal Subjects
Status: Enrolling
Updated:  8/16/2016
Celerion
mi
from
Neptune, NJ
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®), to Assess the Dose Proportionality of Epanova™, and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple Doses of Epanova™ and Vascepa® in Healthy Normal Subjects
Status: Enrolling
Updated: 8/16/2016
Celerion
mi
from
Neptune, NJ
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
Minneapolis Medical Research Foundation
mi
from
Minneapolis, MN
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
Minneapolis Medical Research Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
Columbia University
mi
from
New York, NY
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
Wake Forest University
mi
from
Winston-Salem, NC
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
Veterans Affairs
mi
from
Memphis, TN
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
Veterans Affairs
mi
from
Memphis, TN
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
Univ of Washington
mi
from
Seattle, WA
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated:  11/21/2016
McMaster University
mi
from
Hamilton,
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Status: Enrolling
Updated: 11/21/2016
McMaster University
mi
from
Hamilton,
Click here to add this to my saved trials
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
Status: Enrolling
Updated:  12/14/2016
Tufts University School of Medicine
mi
from
Boston, MA
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
Status: Enrolling
Updated: 12/14/2016
Tufts University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated:  2/2/2017
PRA Health Sciences
mi
from
Lenexa, KA
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated: 2/2/2017
PRA Health Sciences
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated:  2/2/2017
PRA Health Sciences
mi
from
Marlton, NJ
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated: 2/2/2017
PRA Health Sciences
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated:  2/2/2017
Clinical Pharmacology of Miami
mi
from
Miami, FL
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated: 2/2/2017
Clinical Pharmacology of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated:  2/2/2017
PRA Health Sciences
mi
from
Salt Lake City, UT
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Status: Enrolling
Updated: 2/2/2017
PRA Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Hartford, CT
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Kansas City, KA
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Rochester, MN
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Portland, OR
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Aurora, CO
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
Clinical Research Facility
mi
from
Scarborough, ME
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated:  2/6/2017
mi
from
Dresden,
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy
Status: Enrolling
Updated: 2/6/2017
mi
from
Dresden,
Click here to add this to my saved trials
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Grandville, MI
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Grandville, MI
Click here to add this to my saved trials
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated:  2/7/2017
Research Site
mi
from
Heidelberg,
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated: 2/7/2017
Research Site
mi
from
Heidelberg,
Click here to add this to my saved trials
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Kansas City, KA
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Portland, OR
Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Dietary Protein Sources and Atherogenic Dyslipidemia
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia
Status: Enrolling
Updated:  2/14/2017
Cholesterol Research Center, Children's Hospital Research Institute
mi
from
Berkeley, CA
Dietary Protein Sources and Atherogenic Dyslipidemia
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia
Status: Enrolling
Updated: 2/14/2017
Cholesterol Research Center, Children's Hospital Research Institute
mi
from
Berkeley, CA
Click here to add this to my saved trials
Soda and Milk Study
Effects of Replacing Sugar Sweetened Beverages With Milk on Metabolic Factors in Overweight and Obese Adolescents
Status: Enrolling
Updated:  2/14/2017
Cholesterol Research Center
mi
from
Berkeley, CA
Soda and Milk Study
Effects of Replacing Sugar Sweetened Beverages With Milk on Metabolic Factors in Overweight and Obese Adolescents
Status: Enrolling
Updated: 2/14/2017
Cholesterol Research Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
Achieve Clinical Research
mi
from
Birmingham, AL
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
Cardiovascular Associates of the Southeast, LLC
mi
from
Birmingham, AL
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
Cardiovascular Associates of the Southeast, LLC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
Southwest Heart Group
mi
from
Tucson, AZ
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
Southwest Heart Group
mi
from
Tucson, AZ
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
ARA- Arizona Research Associates
mi
from
Tucson, AZ
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
ARA- Arizona Research Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
Diagnamics Inc.
mi
from
Encinitas, CA
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
Diagnamics Inc.
mi
from
Encinitas, CA
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
Encompass Clinical Research North Coast
mi
from
Encinitas, CA
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
Encompass Clinical Research North Coast
mi
from
Encinitas, CA
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
MD Studies, Inc.
mi
from
Fountain Valley, CA
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
MD Studies, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  2/16/2017
Alliance Research Centers
mi
from
Laguna Hills, CA
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 2/16/2017
Alliance Research Centers
mi
from
Laguna Hills, CA
Click here to add this to my saved trials